Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $7.1352W HIGH $17.40
Volume
104.05 K
Value Traded
847.31 K
Short % Float
0.67%
-3.76%Week
-15.38%1 Month
-16.52%3 Month
-18.21%6 Month
+218.57%5 Year
+171.1%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
473.25 M
EPS (TTM)
0.23
P/E Ratio
51.83
Ent. Value
555.47 M
Total Shares
40.21 M
Float Shares
29.59 M
Insiders
26.50%
Institutions
15.65%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
BWAY Catalyst Timeline
Dated clinical, regulatory and corporate events for BrainsWay Ltd.
Catalyst Timeline
Dated clinical, regulatory & corporate events for BrainsWay Ltd.
6Total events
1Upcoming
1Tier-1 (high impact)
2026 to 2026Coverage
Upcoming catalysts 1
TBD
T2Timing Guidance
Subscribe to view catalyst details
Event history 5
▲PublicationPresentation
Publication of pilot study results of Deep TMS in MDD with comorbid early-stage Alzheimer's disease in the Journal of Geriatric Psychiatry and Neurology
Major Depressive Disorder with comorbid early-stage Alzheimer's diseasesource ↗
▲Full ResultsClinical Data
Pilot study results of Deep TMS in MDD with comorbid early-stage Alzheimer's published in Journal of Geriatric Psychiatry and Neurology
Major Depressive Disorder with comorbid early-stage Alzheimer's diseasesource ↗
▲Biomarker DataClinical Data
QEEG showed reduced delta power in right temporal lobe and increased alpha coherence after Deep TMS
Major Depressive Disorder with comorbid early-stage Alzheimer's diseasesource ↗
▲PublicationPresentation
Publication of secondary analysis on suicidality in Journal of Affective Disorders
Major Depressive Disordersource ↗
▲Poster PresentationPresentation
Poster presentation of real-world data on Deep TMS in comorbid PTSD and MDD
comorbid PTSD and MDDsource ↗
Past FDA Catalysts and PDUFA Decisions
How BWAY actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
F19 / 100
Pipeline Score
$42M
Pipeline Value
Not rated
Valuation Signal
1
Drugs Scored
0.1x
rNPV / MCap
Top 95%
Micro Cap(rank 627 of 660)
Percentile Rank
BrainsWay Ltd. has significant pipeline risk (19/100), with $173M risk-adjusted pipeline value, led by Deep TMS in Machado Joseph Disease (SCA3) (Phase 2).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Deep TMS UnknownCompletedNCT02039206 | Machado Joseph Disease (SCA3) | Phase 2 | COMPLETED | 20 | Jun 1, 2016 |
Clinical Trial Results
Readouts, endpoints and source filings for every BWAY program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| Deep TMS | Major Depressive Disorder and early-stage Alzheimer's disease | 2026-09-08 | response rate: 83.3%; remission rate: 50%Read More | BrainsWay Reports Promising Pilot Study Results in Patients with Depression and Comorbid Early-Stage Alzheimer’s Disease Treated with Deep TMS™Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Moiseyev GiladOfficer (Chief Technology Officer) | Sell | -5,000 53,098 held | $0.00 | 06/15/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in BWAY
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| DAFNA Capital Management LLC | 0.1 % (-50 %) | 246.00 K | 12.96 K | -77.24% ( -44.00 K) |
BWAY Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How BWAY ranks across every disease it competes in
Competitive Position is a premium feature
See how BWAY ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialBWAY News
BWAYBrainsWay Reports Promising Pilot Study Results in Patients with Depression and Comorbid Early-Stage Alzheimer’s Disease Treated with Deep TMS™
BrainsWay Ltd. announced positive results from a pilot study of its Deep TMS technology in patients with Major Depressive Disorder and early-stage Alzheimer's disease. The study showed an 83.3% response rate and a 50% remission rate in depressive symptoms, alongside significant changes in brain activity. These findings suggest potential for further research, although the treatment is not FDA-cleared for Alzheimer's.
Read more →BWAYBrainsWay Deep TMS™ Study Shows 70% Reduction in Patients Experiencing Suicidal Ideation
BrainsWay Ltd. announced a study showing a 70% reduction in suicidal ideation among patients with Major Depressive Disorder treated with Deep TMS. The peer-reviewed data revealed significant improvements in suicidality outcomes, with reductions observed in both the SWIFT accelerated protocol and standard Deep TMS treatment. This adds to the growing evidence supporting Deep TMS as a viable option for addressing suicidality in depression.
Read more →BWAY▼ -8.6%on this news
BrainsWay to Report Second Quarter 2026 Financial Results on August 12, 2026
BrainsWay Ltd. will report its second quarter 2026 financial results on August 12, 2026. The company will host a conference call at 8:30 AM ET to discuss these results and provide updates on its operations. BrainsWay is recognized for its advanced neurostimulation treatments and has multiple FDA-cleared indications.
Read more →BWAYBrainsWay Announces Strategic Investment in Radial Health, Inc.
BrainsWay Ltd. has announced a $3 million minority equity investment in Radial Health, Inc., a management services organization focused on Brain Medicine clinics. This investment is part of Radial's Series A financing and aims to enhance access to advanced psychiatric care. BrainsWay's CEO emphasized the importance of this investment in expanding awareness and access to noninvasive mental health treatments.
Read more →BWAYBrainsWay Announces Minority-Stake Investment in Sound Minds Behavioral
BrainsWay Ltd. has announced a $500,000 minority investment in Sound Minds Behavioral, a behavioral health platform. This partnership aims to enhance access to interventional psychiatry solutions and support the growth of Sound Minds. Both companies express optimism about the collaboration's potential to improve mental health care delivery.
Read more →BWAYBrainsWay Presents Positive Data from Largest Real-World Study of Deep TMS™ in Patients with Comorbid PTSD and Major Depressive Disorder
BrainsWay Ltd. presented positive data from a large real-world study on Deep TMS for patients with comorbid PTSD and Major Depressive Disorder. The study found that 83.5% of participants experienced significant reductions in PTSD symptoms, with an average decrease of 52%. Additionally, there were notable improvements in depression symptoms, indicating the potential effectiveness of Deep TMS in treating these co-occurring conditions.
Read more →BWAYBrainsWay Reports Favorable Coverage for Accelerated Deep TMS™ Rises to Over 57 Million Covered Lives
BrainsWay Ltd. has announced an expansion in coverage for its SWIFT Accelerated Deep TMS protocol, now reaching over 57 million covered lives across the U.S. This includes a new policy in South Carolina covering 2 million members. The company emphasizes the importance of this milestone in improving patient access to Deep TMS therapies for conditions like major depressive disorder and obsessive-compulsive disorder.
Read more →BWAYBrainsWay Presents First SWIFT™ Accelerated Deep TMS 12-Month Durability Data at Clinical TMS Society Annual Meeting
BrainsWay presented new 12-month durability data for its SWIFT™ Deep TMS protocol at the Clinical TMS Society Meeting. The study showed that over 80% of patients remained in remission, with significant improvements in functional impairment. This research highlights the long-term benefits of the SWIFT™ protocol compared to traditional methods, reinforcing its efficacy in treating Major Depressive Disorder.
Read more →BWAYBrainsWay Announces Minority-Stake Investment in Hopemark Health
BrainsWay Ltd. has announced a strategic investment of $1.5 million in Hopemark Health, with potential for an additional $1.5 million. This partnership aims to enhance access to advanced mental health treatments and improve patient outcomes. Both companies express optimism about the collaboration, which aligns with BrainsWay's goal of expanding its influence in interventional psychiatry.
Read more →BWAYFrom an innovative technology to a fast - growing ARR company Investor Deck May 2026 Nasdaq/TASE: BWAY Investor Deck | May 2026
BrainsWay presented their investor deck for May 2026, highlighting its continuous growth and profitability. The company reported a 35% revenue increase to $15.5 million in Q1 2026 and aims for total revenue of $66 million to $68 million for the year. With expanding treatment center installations and reinforcing its financial standing, BrainsWay is progressing through various clinical trials. However, the company remains cautious about potential uncertainties that could impact future performance.
Read more →BWAYBrainsWay Reports First Quarter 2026 Financial Results and Operational Highlights
BrainsWay Ltd. reported a strong financial performance for Q1 2026, with revenue increasing by 35% to $15.5 million and net income more than doubling to $2.3 million. The company also highlighted a significant demand for its Deep TMS systems, shipping a record 117 units. Additionally, BrainsWay reiterated its full-year financial guidance, projecting revenue between $66 million and $68 million.
Read more →BWAYFrom an innovative technology to a fast - growing ARR company Investor Deck March 2026 Nasdaq/TASE: BWAY Investor Deck | March 2026
BrainsWay has reported strong financial results for Q4 2025, demonstrating a 27% year-over-year revenue growth and a net income increase of 161%. The company received FDA clearance for new treatment protocols, further expanding its market capabilities. With a solid installed base of over 1,700 treatment centers, BrainsWay is positioned for continued growth, supported by a 93% customer retention rate. Additionally, the company emphasizes its transition to a high-margin annual recurring revenue model, promising enhanced financial stability going forward.
Read more →BWAYBrainsWay Announces Change in ADS-to-Ordinary Share Ratio
BrainsWay Ltd. announced a change in the ratio of its American Depositary Shares (ADSs) to ordinary shares, shifting from a 2-to-1 to a 1-to-1 ratio effective March 3, 2026. This adjustment aims to simplify the company's capital structure and enhance liquidity for investors. Each existing ADS holder will receive one additional ADS for each ADS held, effectively acting as a 2-for-1 split.
Read more →BWAYAdvanced Noninvasive Neurostimulation Treatments for Mental Health Disorders Investor Deck November 2025 Nasdaq/TASE: BWAY Investor Deck | November 2025
BrainsWay, traded as BWAY, presented its Investor Deck for November 2025, highlighting substantial growth in its neurostimulation treatments for mental health disorders. The company reported a 29% year-over-year revenue increase, with an adjusted EBITDA growth of 81% and a net profit rise of 137%, driven by a robust multi-year lease structure and recent FDA clearance for new treatment protocols. Additionally, BrainsWay has secured a $2.5M NIH grant for research on alcohol use disorder, positioning itself strongly in the mental health market. Future growth strategies include expanding partnerships and introducing its technologies to new clinical settings.
Read more →BWAYA New Era in Brain Disorder Treatment Corporate Presentation Nasdaq/TASE: BWAY August 2025
BrainsWay (BWAY) presented its corporate strategy and financial outlook, highlighting its leadership in noninvasive neurostimulation treatments for mental health disorders. The company reported a revenue increase of 26% year-over-year, reaching $12.6 million in Q2 2025, with raised guidance for the full year. A significant partnership with Valor Equity Partners has secured $20 million in funding, enhancing growth opportunities. BrainsWay's innovative business model, focusing on recurring revenue from long-term contracts, positions it for continued financial stability and expansion in the mental health sector.
Read more →BWAYBrainsWay to Showcase Deep TMS at the 2025 American Psychiatric Association Annual Meeting in Los Angeles
BrainsWay will showcase its Deep TMS technology at the 2025 American Psychiatric Association Annual Meeting in Los Angeles. The company will conduct live demonstrations at its booth and participate in a Master Course focused on advanced psychiatric treatments. Key presentations will be made by Dr. Richard Bermudes and Dr. Colleen Hanlon, emphasizing BrainsWay's commitment to mental health innovation.
Read more →BWAYHartum Street, Bynet Building, 3rd Floor
19 Hartum Street, Bynet Building, 3rd Floor Har HaHotzvim, Jerusalem 9777518 NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS To Be Held on December 22, 2021 The Annual General Meeting of Shareholders of BrainsWay Ltd. (the "Company"), will be held at the offices of the Comp
Read more →BWAYBRAINSWAY LTD. CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS AS OF SEPTEMBER 30, 2020 U.S. DOLLARS IN THOUSANDS UNAUDITED INDEX Page Condensed Interim Consolidated Statements of Financial Position 2 Condensed Inter
INTERIM CONSOLIDATED FINANCIAL STATEMENTS OF SEPTEMBER 30, 2020 DOLLARS IN THOUSANDS Page Condensed Interim Consolidated Statements of Financial Position 2 Condensed Interim Consolidated Statements of Comprehensive Loss 3 Condensed Interim Consolidated Statements of Changes i
Read more →BWAYBrainsway Ltd. Announces Pricing of Initial Public Offering of 2.5 Million American Depositary Shares JERUSALEM, ISRAEL
Brainsway Ltd. Announces Pricing of Initial Public Offering of 2.5 Million American Depositary Shares JERUSALEM, ISRAEL, April 16, 2019 Brainsway Ltd. (NASDAQ: BWAY and TASE: BRIN) ( Brainsway ) today announced that it has priced its initial public offering of 2,500,000 America
Read more →About BrainsWay Ltd.
BIOPHARMAWATCH ELITE PLUS
Trade the next BWAY catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime